The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area ...
A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...
The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...
177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback